Therapeutic chemokine receptor antagonists

Details Therapeutic chemokine receptor antagonists Therapeutic chemokine receptor antagonists

2005-05-23

2008-09-09

Stucker, Jeffrey (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S007600, C514S008100, C514S016700, C514S903000

Reexamination Certificate

active

07423011

ABSTRACT:
The invention provides a variety of therapeutic uses for CXCR4 antagonists. In various embodiments, CXCR4 antagonists may be used as therapeutically as follows, or to manufacture a medicament for such therapeutic treatments: reducing interferon gamma production by T-cells, treatment of an autoimmune disease, treatment multiple sclerosis, treatment of cancer, inhibition of angiogenesis. The invention provides corresponding methods of medical treatment, in which a therapeutic dose of a CXCR4 antagonist is administered in a pharmacologically acceptable formulation. Accordingly, the invention also provides therapeutic compositions comprising a CXCR4 antagonist and a pharmacologically acceptable excipient or carrier. The CXCR4 antagonists for use in the invention may be peptide compounds comprising a substantially purified peptide fragment, modified fragment, analogue or pharmacologically acceptable salt of SDF-1.

REFERENCES:
patent: 2530369 (1950-11-01), Simons et al.
patent: 2760992 (1956-08-01), Schoeffel et al.
patent: 4554101 (1985-11-01), Hopp et al.
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5082670 (1992-01-01), Gage et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5401651 (1995-03-01), Walz
patent: 5563048 (1996-10-01), Honjo et al.
patent: 5756084 (1998-05-01), Honjo et al.
patent: 5807744 (1998-09-01), Bernemen et al.
patent: 5856301 (1999-01-01), Craig et al.
patent: 5871723 (1999-02-01), Strieter et al.
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 5962462 (1999-10-01), Mills et al.
patent: 5990163 (1999-11-01), Evans et al.
patent: 6013644 (2000-01-01), Mills et al.
patent: 6022848 (2000-02-01), Kozlov et al.
patent: 6046185 (2000-04-01), Burgoyne et al.
patent: 6124319 (2000-09-01), MacCoss et al.
patent: 6132987 (2000-10-01), Charo et al.
patent: 6133319 (2000-10-01), Widdowson et al.
patent: 6136827 (2000-10-01), Caldwell et al.
patent: 6140349 (2000-10-01), Caldwell et al.
patent: 6166037 (2000-12-01), Budhu et al.
patent: 6204294 (2001-03-01), Bryan et al.
patent: 6356887 (2002-03-01), Berenson et al.
patent: 6515001 (2003-02-01), Saxena et al.
patent: 6613742 (2003-09-01), Huang et al.
patent: 6693134 (2004-02-01), Saxena et al.
patent: 6875738 (2005-04-01), Clarke Lewis et al.
patent: 6946445 (2005-09-01), Clarke Lewis et al.
patent: 2002/0156034 (2002-10-01), Tudan et al.
patent: 2002/0165123 (2002-11-01), Tudan et al.
patent: 2003/0004136 (2003-01-01), Saxena et al.
patent: 2003/0045550 (2003-03-01), Saxena et al.
patent: 2003/0092674 (2003-05-01), Saxena et al.
patent: 2003/0125380 (2003-07-01), Saxena et al.
patent: 2003/0148940 (2003-08-01), Tudan et al.
patent: 2003/0202963 (2003-10-01), Crystal et al.
patent: 2005/0059584 (2005-03-01), Merzouk et al.
patent: 2005/0164935 (2005-07-01), Clarke Lewis et al.
patent: 2005/0265969 (2005-12-01), Clarke Lewis et al.
patent: 2006/0014682 (2006-01-01), Clarke Lewis et al.
patent: WO 89/02468 (1989-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 90/06757 (1990-06-01), None
patent: WO 91/04274 (1991-04-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 93/10234 (1993-05-01), None
patent: WO 93/13206 (1993-07-01), None
patent: WO 95/05452 (1995-02-01), None
patent: WO 95/09236 (1995-04-01), None
patent: WO 96/40772 (1996-12-01), None
patent: WO 97/28257 (1997-08-01), None
patent: WO 97/28258 (1997-08-01), None
patent: WO 98/04684 (1998-02-01), None
patent: WO 98/04698 (1998-02-01), None
patent: WO 98/09642 (1998-03-01), None
patent: WO 95/51705 (1998-11-01), None
patent: WO 99/47158 (1999-09-01), None
patent: WO 00/09152 (2000-02-01), None
patent: WO 00/66112 (2000-09-01), None
patent: WO 01/76615 (2001-10-01), None
patent: WO 01/85196 (2001-11-01), None
patent: WO 2004/024088 (2004-03-01), None
Acsadi G. et al, “Human Dystrophin Expression in MDX Mice After Intramuscular Injection of DNA Constructs” (1991)Naturevol. 352, 815-818.
Aiuiti, et al. “The Chemokine SDF-1 is a Chemoattractant for Human CD34+Hematopoietic Progentior Cells and Provides a New Mechanism to Explain the Mobilization of CD34+Progenitors to Peripheral Blood”J. Exp. Med. (1996) vol. 185, pp. 111-120.
Aiuti, et al. “Expression of CXCR4, the Receptor for Stromal Cell-Derived Factor-1 on Fetal and Adult Human Lympho-hematopoietic Progenitors”Eur. J. Immunol(Jun. 1999) vol. 29(6), pp. 1823-1831.
Alkhatib, G. et al, “CC CKR5: A RANTES, MIP-1α, MIP-β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1” (1996)Sciencevol. 272, 1955-1958.
Allen, M. et al, “High Throughput Fluorescence Polarization: A Homogeneous Alternative to Radioligand Binding for Cell Surface Receptors” (2000)J. Biomolecular Screeningvol. 5 No. 2, 63-69.
Alleva, et al. “Intrinsic Defects in Macrophage IL-12 Production Associated with Immune Dysfunction in the MRL/++ and New Zealand Black/White F1Lupus-Prone Mice and theLeishmania major-Susceptible BALB/c Strain1”J. Immunol. (1998) vol. 161, pp. 6878-6884.
Anderlini, P. et al, “Allogenic Blood Stem Cell Transplantation: Considerations for Donors” (1997)Bloodvol. 90 No. 3, 903-908.
Anderson, W. et al, “The Best of Times, the Worst of Times” (2000)Sciencevol. 288, 627-629.
Arenzana-Selsdedos, F. et al, “HIV Blocked by Chemokine Antagonist” (1996)Naturevol. 383, 400.
Armentano, et al. “Expression of Human Factor IX in Rabit Hepatocytes by Retrovirus-mediated Gene Transfer: Potential for Gene Therapy of Hemophilia B”Proc. Natl. Acad. Sci. USA(1990) vol. 87, pp. 6141-6145.
Ascadi, et al. “Human Dystrophin Expression in mdx Mice After Intramuscular Injection of DNA Constructs”Nature(1991) vol. 352, pp. 815-818.
Ausubel, et al. “Current Protocols in Molecular Biology”Greene Publishing Associates(1989) Sections 9.10-9.14.
Avenarius, H. et al, “Granulocyte Colony-stimulating Factor Enhances the Expression of CD62 on Platelets in vivo” (1993)Inter. J. Hematologyvol. 58, 189-196.
Baggiolini, M. “Chemokines and Leukocyte Traffic” (1998)Naturevol. 392, 565-568.
Baird, et al. “The Role of Cytokine Receptor Signaling Lymphocyte Development”Cur. Opin. Immunol. (Apr. 1999) vol. 11(2), pp. 157-166.
Balasa, et al. “Interferon γ (IFN-γ)is Necessary for the Genesis of Acetylcholine Receptor-induced Clinical Experimental AutoimmuneMyashenia gravisin Mice”J. Exp. Med. (Aug. 1997) vol. 186(3), pp. 385-391.
Baldari, et al. “The Novel Leader Peptide Which Allows Efficient Secretion of a Fragment of Human Interleukin 1β inSaccharomyces cerevisiae” The EMBO Journal(1987) vol. 6, pp. 229-234.
Barbier, J. et al, “Bioactivities and Secondary Structures of Constrained Analogues of Human Parathyroid Hormone: Cyclic Lactams of the Receptor Binding Region” (1997)J. Med. Chem. vol. 40 No. 9, 1373-1380.
Barbier, J. et al, “Structure and Activities of Constrained Analogues of Human Parathyroid Hormone and Parathyroid Hormone-Related Peptide: Implications for Receptor-Activating Conformations of the Hormones” (2000)Biochemistry 2000vol. 39 No. 47, 14522-14530.
Barnes, D. et al, “Polyclonal Antibody Directed Against Human RANTES Ameliorates Diseases in the Lewis Rat Adjuvant-Induced Arthritis Model” (1998)J. Clin. Invest. vol. 101 No. 12, 2910-2919.
Berkner, et al. “Development of Adenovirus Vectors for the Expression of Heterologous Genes”Bio Techniques(1988) vol. 6, pp. 616-627.
Blease, K. et al, “Airway Remodeling Is Absent in CCR1--/-Mice During Chronic Fungal Allergic Airway Disease” (2000)J. Immunol. vol. 165, 1564-1572.
Bleul, et al. “A Highly Efficacious Lymphocyte Chemoattractant, Stromal Cell-derived Factor 1 (SDF-1)”Nature(1996) vol. 184, pp. 1101-1109.
Bleul, et.al. “The Lymphocyte Chemoat

Affiliated with

Also associated with

Rating

Therapeutic chemokine receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic chemokine receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic chemokine receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3989027